Pipeline

Mechanism of Action (MOA)
Indication
Preclinical
Phase I
Phase II
Phase III / Pivotal

Cosibelimab

Anti-PD-L1 Antibody

cSCC

Metastatic

Single Agent

cSCC

Locally
Advanced

Single Agent

NSCLC 1L

Metastatic/
Non-Squamous

Cosibelimab +
Pemetrexed +
Platinum

NSCLC

EGFR mut+

Cosibelimab +
Chemotherapy

Olafertinib

3rd Generation EGFR Inhibitor

NSCLC

1L EGFR mut+

Single Agent

NSCLC

EGFR mut+

Cosibelimab +
Olafertinib

Earlier Stage Programs

Earlier Stage Programs

CK-103

CK-302

CK-303

BET Inhibitor

Solid Tumor

Anti-GITR

Solid Tumor

Anti-CAIX

Solid Tumor

© 2021 Checkpoint Therapeutics Inc.